secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tracon Pharmaceuticals, Inc. (—)
CIK:        0001394319
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059509
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TRACON reports Q1 net loss $3.2M, cash $8.0M; ENVASARC final data due Q3 2024
-----------------------------------------------------------------------------

- Net loss for Q1 2024 was $3.2M, down from $8.5M in Q1 2023.
- Cash, cash equivalents and restricted cash were $8.0M at March 31, 2024, expected to fund operations late into Q3 2024.
- ENVASARC Phase 2 pivotal trial fully enrolled; final response assessment data expected in Q3 2024.
- Interim data: ORR 11% by investigator and 5.5% by BICR; median duration of response >6 months.
- Nasdaq listing extension granted through June 3, 2024, subject to reverse stock split and S-1 filing (both completed in April 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/0000950170-24-059509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/tcon-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer